{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-25-000094","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.599316+00:00","generated_at":"2026-05-17T01:32:28.247703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance","bullets":["Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.","GAAP net loss $(5.4)M ($(0.07)/diluted share); adjusted EPS $0.54 vs $0.41 YoY.","Codman Specialty Surgical revenues $292.6M (+8.1% reported); Tissue Technologies $109.5M (-0.5% reported).","Full-year 2025 revenue guidance cut to $1.620B-$1.640B (organic growth -1.6% to -0.4%); adj EPS $2.19-$2.24.","Relaunched PriMatrix and Durepair ahead of schedule; Braintree facility on track for production in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-25-000094","json":"https://secwatch.observer/filing/0000917520-25-000094.json","markdown":"https://secwatch.observer/filing/0000917520-25-000094.md","text":"https://secwatch.observer/filing/0000917520-25-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752025000094/0000917520-25-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752025000094/iart-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:32:28.247703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}